Rani Therapeutics Holdings financials
$0.8003+3.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0.00 | $0.00 | $2.7M |
| Gross profit | $1.6M | $1.0M | $0.00 | $0.00 | $2.7M |
| Gross margin | 100.0% | 100.0% | — | — | 100.0% |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M | -$51.6M |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M | -$8.3M |
| Net margin | −1817.1% | −2920.0% | — | — | −306.6% |
| Diluted EPS | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 |
| EBITDA | -$37.4M | -$48.6M | -$65.3M | -$62.1M | -$51.1M |
| Operating cash flow | -$18.7M | -$35.5M | -$51.2M | -$46.5M | -$32.2M |
| Free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M | -$32.8M |
| Diluted shares | 66.1M | 28.5M | 25.5M | 23.8M | 19.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $18.6M | $3.8M | $5.9M | $27.0M | $117.5M |
| Short-term investments | $31.1M | $23.9M | $42.7M | $71.5M | $0.00 |
| Total debt | $0.00 | $24.6M | $29.4M | $29.1M | $0.00 |
| Total assets | $58.6M | $36.6M | $57.9M | $108.0M | $124.2M |
| Total liabilities | $17.1M | $33.1M | $32.5M | $34.0M | $2.6M |
| Shareholders' equity | $41.5M | $3.5M | $25.4M | $74.0M | $121.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology